BioCryst Pharmaceuticals, Inc. (BCRX) Key Metrics
BCRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.99B
- Enterprise value
- $2.63B
- P/E (TTM)
- —
- Forward P/E
- 14.5
- PEG ratio
- 9.39
- Price / sales
- 2.1 10-yr median 12.0
- Price / book
- 56.6
- EV / EBITDA
- 7.2
- Dividend yield
- —
- Beta
- 0.55
BCRX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBCRX valuation Price multiples at each fiscal year-end price.
Price / sales−43.5%
1.9
2025 · hover or tap a bar for each year
20162025
EV / EBITDA−96.7%
5.4
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+22.6 pts
19.2%
2025 · hover or tap a bar for each year
20162025
BCRX returns How much profit the business earns on the capital it uses.
Return on invested capital+768.8 pts
752.8%
2025 · hover or tap a bar for each year
20162025
Return on assets+70.2 pts
52.5%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+49.2 pts
37.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover+94.6%
1.74
2025 · hover or tap a bar for each year
20162025
BCRX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+83.5%
$4.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
$1.21
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
$1.50
2025 · hover or tap a bar for each year
20162025
Book value per share
−$0.55
2025 · hover or tap a bar for each year
20162025
Shares outstanding+5.7%
218.6M
2025 · hover or tap a bar for each year
20162025
BCRX financial health Debt, liquidity and how easily interest is covered.
Net debt−$356.2M
$164.1M
2025 · hover or tap a bar for each year
20162025
Net debt / EBITDA−40.16
0.47
2025 · hover or tap a bar for each year
20162025
Current ratio−21.6%
2.06
2025 · hover or tap a bar for each year
20162025
Interest coverage
4.3
2025 · hover or tap a bar for each year
20162025
Debt / assets−50.2%
0.85
2025 · hover or tap a bar for each year
20162025
BCRX efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−16 days
39 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−408 days
129 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−213 days
263 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−212 days
-95 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.3%
2025 · hover or tap a bar for each year
20162025
BCRX valuation history
Fiscal year-endToday10-year median
BCRX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BCRX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BCRX price vs earnings per share
Share price at year-endEPS (right axis)
BCRX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.70B | $1.55B | $1.15B | $2.13B | $2.48B | $1.25B | $398.8M | $832.7M | $414.7M | $466.5M |
| Enterprise value | $1.87B | $2.07B | $1.59B | $2.45B | $2.57B | $1.10B | $347.2M | $767.7M | $313.7M | $456.7M |
| P/E ratio | 6.5 | — | — | — | — | — | — | — | — | — |
| Price / sales | 1.9 | 3.4 | 3.5 | 7.9 | 15.8 | 70.0 | 8.2 | 40.3 | 16.5 | 17.7 |
| Price / book | — | — | — | — | — | — | 10.4 | — | — | — |
| Price / free cash flow | 5.2 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 5.2 | — | — | — | — | — | — | — | — | — |
| EV / sales | 2.1 | 4.6 | 4.8 | 9.1 | 16.3 | 61.6 | 7.1 | 37.2 | 12.5 | 17.3 |
| EV / EBITDA | 5.4 | 162.0 | — | — | — | — | — | — | — | — |
| EV / free cash flow | 5.7 | — | — | — | — | — | — | — | — | — |
| Earnings yield | 15.5% | −5.7% | −19.7% | −11.6% | −7.4% | −14.7% | −27.3% | −12.2% | −15.9% | −11.8% |
| Free cash flow yield | 19.2% | −3.4% | −8.5% | −7.6% | −5.8% | −11.1% | −22.5% | −11.2% | −10.0% | −12.6% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $7.80 | $7.52 | $5.99 | $11.48 | $13.85 | $7.45 | $3.45 | $8.07 | $4.91 | $6.33 |
| Per share | ||||||||||
| Revenue per share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | $0.30 | $0.36 |
| Earnings per share | $1.21 | −$0.43 | −$1.18 | −$1.33 | −$1.03 | −$1.09 | −$0.94 | −$0.98 | −$0.78 | −$0.75 |
| Operating cash flow per share | $1.51 | −$0.25 | −$0.50 | −$0.87 | −$0.79 | −$0.82 | −$0.77 | −$0.90 | −$0.49 | −$0.73 |
| Free cash flow per share | $1.50 | −$0.26 | −$0.51 | −$0.88 | −$0.81 | −$0.82 | −$0.78 | −$0.90 | −$0.49 | −$0.80 |
| Cash per share | $1.26 | $1.55 | $2.02 | $2.28 | $2.83 | $1.80 | $1.18 | $1.23 | $1.84 | $0.86 |
| Book value per share | −$0.55 | −$2.30 | −$2.37 | −$1.58 | −$0.60 | −$0.12 | $0.33 | −$7.09 | −$7.48 | −$7.68 |
| Tangible book value per share | −$0.55 | −$2.30 | −$2.37 | −$1.58 | −$0.60 | −$0.12 | $0.33 | −$7.09 | −$7.48 | −$7.68 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.07 |
| Debt per share | $2.01 | $4.07 | $4.29 | $3.99 | $3.31 | $0.90 | $0.73 | $0.60 | $0.65 | $0.73 |
| Shares outstanding | 218.6M | 206.7M | 192.2M | 185.9M | 179.1M | 167.3M | 115.6M | 103.2M | 84.5M | 73.7M |
| Change in shares outstanding | +5.7% | +7.5% | +3.4% | +3.8% | +7.1% | +44.7% | +12.0% | +22.2% | +14.6% | +1.1% |
| Returns & profitability | ||||||||||
| Return on invested capital (ROIC) | 752.8% | −16.0% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | 52.5% | −17.6% | −42.5% | −43.4% | −39.9% | −71.7% | −67.6% | −62.3% | −49.1% | −51.4% |
| Return on tangible assets | 51.3% | −18.1% | −43.8% | −44.9% | −31.3% | −54.6% | −62.1% | −69.0% | −36.9% | −61.4% |
| Free cash flow margin | 37.4% | −11.8% | −29.4% | −60.3% | −92.0% | −773.2% | −184.1% | −450.0% | −164.7% | −222.8% |
| Income quality (OCF / net income) | 1.25 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $438.9M | $841.4M | $825.1M | $741.5M | $593.2M | $150.9M | $84.7M | $61.8M | $54.7M | $53.7M |
| Cash & short-term investments | $274.7M | $321.1M | $389.0M | $424.3M | $507.6M | $300.4M | $136.2M | $126.8M | $155.7M | $63.6M |
| Net debt | $164.1M | $520.4M | $436.2M | $317.1M | $85.6M | −$149.5M | −$51.6M | −$65.0M | −$101.0M | −$9.9M |
| Debt / equity | — | — | — | — | — | — | 2.21 | — | — | — |
| Debt / assets | 0.85 | 1.72 | 1.60 | 1.35 | 1.01 | 0.45 | 0.48 | 0.42 | 0.31 | 0.60 |
| Net debt / EBITDA | 0.47 | 40.63 | — | — | — | — | — | — | — | — |
| Current ratio | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | 1.65 | 1.68 | 1.23 |
| Quick ratio | 2.03 | 2.58 | 3.12 | 4.63 | 5.31 | 3.00 | 1.76 | 1.62 | 2.18 | 1.22 |
| Interest coverage | 4.3 | -0.0 | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | -6.7 | -7.5 |
| Working capital | $208.3M | $261.6M | $346.0M | $411.0M | $462.4M | $218.1M | $72.0M | $44.9M | $50.6M | $12.6M |
| Invested capital | $45.0M | $44.4M | −$19.4M | $22.5M | −$21.3M | −$168.7M | −$13.3M | −$797.0M | −$732.8M | −$575.9M |
| Tangible asset value | −$119.2M | −$475.9M | −$455.5M | −$294.6M | −$107.0M | −$19.3M | $38.3M | $49.2M | $83.8M | $1.6M |
| Net current asset value | −$229.0M | −$544.4M | −$476.5M | −$328.1M | −$129.0M | −$30.2M | $27.3M | $16.7M | $30.9M | −$21.3M |
| Graham net-net per share | −$1.26 | −$2.82 | −$2.74 | −$1.98 | −$0.88 | −$0.26 | $0.14 | $0.32 | $0.56 | −$0.24 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.3% | 0.2% | 0.7% | 0.5% | 1.5% | 2.9% | 0.7% | 1.8% | 1.3% | 20.0% |
| Capex / operating cash flow | 0.7% | — | — | — | — | — | — | — | — | — |
| Capex / depreciation | 1.78 | 0.90 | 1.31 | 0.94 | 3.07 | 0.69 | 0.47 | 0.48 | 0.47 | 10.93 |
| Stock-based compensation / revenue | 9.7% | 14.5% | 16.8% | 16.5% | 22.0% | 83.1% | 36.3% | 45.5% | 50.1% | 32.2% |
| R&D / revenue | 19.0% | 38.7% | 65.3% | 93.5% | 132.9% | 690.3% | 219.2% | 411.0% | 265.9% | 231.5% |
| SG&A / revenue | 39.9% | 59.0% | 64.4% | 58.8% | 75.6% | 381.4% | 76.0% | 142.9% | 55.3% | 42.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 38.8 | 55.1 | 59.2 | 53.9 | 44.2 | 315.5 | 98.8 | 92.0 | 107.9 | 104.0 |
| Days of inventory on hand | 129.0 | 537.5 | 2,201.1 | 1,199.1 | 573.6 | 935.4 | 142.4 | -14,007.2 | -3,999.5 | 142.8 |
| Days payables outstanding | 262.8 | 475.6 | 1,380.2 | 1,167.0 | 1,168.8 | 3,560.8 | 968.2 | 5,465.7 | 1,137.2 | 918.0 |
| Cash conversion cycle (days) | -95.0 | 117.0 | 880.2 | 86.0 | -551.0 | -2,310.0 | -727.0 | -19,380.9 | -5,028.8 | -671.2 |
| Receivables turnover | 9.41 | 6.63 | 6.16 | 6.77 | 8.26 | 1.16 | 3.69 | 3.97 | 3.38 | 3.51 |
| Payables turnover | 1.39 | 0.77 | 0.26 | 0.31 | 0.31 | 0.10 | 0.38 | 0.07 | 0.32 | 0.40 |
| Inventory turnover | 2.83 | 0.68 | 0.17 | 0.30 | 0.64 | 0.39 | 2.56 | — | — | 2.56 |
| Asset turnover | 1.74 | 0.89 | 0.62 | 0.48 | 0.34 | 0.07 | 0.30 | 0.13 | 0.19 | 0.25 |
| Average receivables | $92.9M | $68.0M | $53.8M | $40.0M | $19.0M | $15.4M | $13.2M | $5.2M | $7.4M | $7.5M |
| Average payables | $13.7M | $16.3M | $17.6M | $21.1M | $23.3M | $16.4M | $10.9M | $7.1M | $5.3M | $6.8M |
| Average inventory | $6.7M | $18.4M | $28.1M | $21.7M | $11.4M | $4.3M | $1.6M | −$18.1M | −$18.6M | $1.1M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BCRX's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BCRX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), BioCryst Pharmaceuticals traded at 6.5 times earnings. BioCryst Pharmaceuticals earned a return on invested capital of 752.8% in fiscal 2025. It ended the year with $438.9 million of debt and $274.7 million in cash and short-term investments, net debt of $164.1 million. The share count rose 196.6% from 73.7M to 218.6M over 9 years.
See the BCRX income statement, the BCRX chart for price history, or the BCRX stock overview for the latest quote and news.
BCRX key metrics FAQ
What is BioCryst Pharmaceuticals's P/E ratio?
BioCryst Pharmaceuticals traded at 6.5 times earnings at the end of fiscal 2025.
What is BioCryst Pharmaceuticals's EV/EBITDA?
BioCryst Pharmaceuticals's enterprise value was 5.4 times EBITDA at the end of fiscal 2025 (enterprise value $1.9 billion, EBITDA $347.7 million); the current EV/EBITDA is 7.2.
What is BioCryst Pharmaceuticals's ROIC?
BioCryst Pharmaceuticals's return on invested capital was 752.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does BioCryst Pharmaceuticals have?
BioCryst Pharmaceuticals had total debt of $438.9 million at the end of fiscal 2025 and $164.1 million of net debt (0.47 times EBITDA).
What is BioCryst Pharmaceuticals's free cash flow yield?
BioCryst Pharmaceuticals generated $327.4 million of free cash flow in fiscal 2025, a free cash flow yield of 19.2% on its market value at year-end ($1.7 billion).
What is BioCryst Pharmaceuticals's current ratio?
BioCryst Pharmaceuticals's current ratio was 2.06 at the end of fiscal 2025: current assets were 2.06 times current liabilities.